Literature DB >> 28392738

The role of laboratory testing in detection and classification of chronic kidney disease: national recommendations.

Vanja Radišić Biljak1, Lorena Honović2, Jasminka Matica3, Branka Krešić4, Sanela Šimić Vojak5.   

Abstract

Chronic kidney disease (CKD) is a common clinical condition with significant adverse consequences for the patient and it is recognized as a significant public health problem. The role of laboratory medicine in diagnosis and management of CKD is of great importance: the diagnosis and staging are based on estimation of glomerular filtration rate (eGFR) and assessment of albuminuria (or proteinuria). Therefore, the joint working group of the Croatian society of medical biochemistry and laboratory medicine and Croatian chamber of medical biochemists for laboratory diagnostics in CKD issued this national recommendation regarding laboratory diagnostics of CKD.
Key factors for laboratories implementing the national guidelines for the diagnosis and management of CKD are:
1. Ensure good communication between laboratory professionals and clinicians, such as nephrologists or specialists in general/family medicine,
2. Ensure all patients are provided with the same availability of laboratory diagnostics,
3. Ensure creatinine assays are traceable to isotope dilution mass spectrometry (IDMS) method and have minimal bias and acceptable imprecision,
4. Select the appropriate GFR estimating formula. Recommended equation is the 2009 Chronic Kidney Disease Epidemiology Collaboration (CKD - EPI) equation,
5. In reporting the key laboratory tests (creatinine, eGFR, urine albumin-to-creatinine ratio, urine protein-to-creatinine ratio) use the appropriate reporting units,
6. Provide adequate information on limitations of creatinine measurement.
The manuscript has been organized to identify critical points in laboratory tests used in basic laboratory diagnostics of CKD and is based on the Kidney Disease: Improving Global Outcomes (KDIGO) 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease.

Entities:  

Keywords:  albuminuria; chronic kidney disease (CKD); proteinuria; recommendations, estimated glomerular filtration rate (eGFR)

Mesh:

Year:  2017        PMID: 28392738      PMCID: PMC5382859          DOI: 10.11613/BM.2017.019

Source DB:  PubMed          Journal:  Biochem Med (Zagreb)        ISSN: 1330-0962            Impact factor:   2.313


Introduction

Chronic kidney disease (CKD) is a common clinical condition with significant adverse consequences for the patient. It is recognized as a significant public health problem throughout the world (). Many publications report the prevalence of CKD in the general population, however there are considerable variation in methods for sampling general population and assessment of kidney function across studies (). This makes comparison of studies rather difficult, however worldwide prevalence of adult CKD is about 10%, reaching up to 50% in high-risk population (). Late recognition and diagnosis of disease inevitably leads to kidney failure (). In this case the only possible therapeutic measure is dialysis or transplantation in health care systems where such treatment is available. In those countries, where access to dialysis and transplantation service may be limited or unavailable, the final consequence of progressive CKD is death. Earlier stages of kidney disease are often asymptomatic and are usually discovered through various comorbid conditions, and may be reversible. It is of great importance, due to right time treatment and improving the quality of life of patients with CKD, but also because of the significant financial savings, to identify disease at an early stage where it is still possible to stop or slow down progression (). Although, to this point, there had not been official complete epidemiological studies conducted regarding CKD (prof. Mirjana Sabljar Matovinović, personal communication), the availability of treatment in Croatia includes both, dialysis and transplantation (). In 2002 the US Kidney Disease Outcomes Quality Initiative (KDOQI) group published the Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification. Update of these guidelines and recommendations: Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease was released in 2012 under the direction of Kidney Disease: Improving Global Outcomes (KDIGO). Our national recommendations for laboratory diagnosis of chronic kidney disease are mainly based on the 2012 KDIGO guidelines, and written permission was obtained to reproduce the parts of the KDIGO guidelines. KDIGO guidelines are the product of cooperation of a large number of international experts who created recommendations, among other things, to be used for good laboratory practice in the diagnosis and management of CKD. Chronic kidney disease is defined as an abnormality of kidney structure or function with implications on the health of an individual, and it is present for more than three months. Chronic kidney disease is a general term for heterogeneous disorders affecting kidney structure and function with variable clinical presentation (). Rational approach to the diagnosis and evaluation of CKD involves simultaneous assessment and monitoring of renal function (through estimated glomerular filtration rate (eGFR), serum creatinine) and kidney damage (albuminuria and/or proteinuria) (Table 1).
Table 1

Criteria for chronic kidney disease (CKD) diagnosis*

Markers of kidney damage(one or more)Albuminuria (AER ≥ 30 mg/24 hours; ACR ≥ 3 mg/mmol)Urine sediment abnormalitiesElectrolyte and other abnormalities due to tubular disordersAbnormalities detected by histologyStructural abnormalities detected by imagingHistory of kidney transplantation
Decreased GFRGFR < 60 mL/min/1.73 m2 (GFR categories G3a - G5)
*Either of the following should be present for > 3 months. AER - albumin excretion rate. ACR - albumin-to-creatinine ratio. GFR - glomerular filtration rate.(Reproduced with permission from KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int, Suppl 2013;3:1-150.)
One of the prominent criteria for the diagnosis of CKD is decreased GFR value (< 60 mL/min/1.73m2). GFR is widely accepted as the best index of kidney function. The normal value in young adult men and woman is approximately 125 mL/min/1.73m2. Values below 15 mL/min/1.73m2 indicate kidney failure and the person can be identified as a candidate for dialysis or renal replacement therapy/kidney transplantation (). The role of laboratory medicine in diagnosis and management of CKD is of great importance because a very simple test can identify people who are at risk of developing CKD. All that is required is measuring the concentration of serum creatinine and reporting of eGFR, using the available predictive equations. For an initial assessment of proteinuria the following measurements are recommended (in descending order of preference): urine albumin-to-creatinine ratio (ACR), or urine protein-to-creatinine ratio (PCR). In all cases an early morning urine sample is preferred, but does not exclude spot urine samples. Measuring the concentration of urine albumin is preferred to measuring the concentration of urine total protein. Use of urine albumin measurement as the preferred test for proteinuria detection will improve the sensitivity, quality, and consistency of the approach to early detection and management of kidney disease. Albumin (or total protein) concentration in the urine sample should be reported in proportion to the concentration of creatinine (ACR or PCR) in the same sample to minimize the influence of the patient’s hydration and the concentration of the urine sample. The reporting of the results is the same for both first morning and spot urine samples, respectively. A positive finding of albuminuria in a random sample of urine needs to be confirmed in the next morning void urine. If a more accurate assessment of albuminuria (or total proteinuria) is required, it is recommended to measure albumin excretion rate (AER) or total protein excretion rate in a timed urine sample (, , ). The choice of a suitable timed sample type should be of a laboratory manager. Adequate sample type, time of collection and instructions for patients should be provided by institution. Some of the other laboratory criteria for diagnosing CKD include urine sediment abnormalities as markers of kidney damage (Table 1). This may include some formed elements, such as renal tubular cells, red blood cells (RBC) casts, white blood cell (WBC) casts, coarse granular casts, wide casts and large numbers of dysmorphic RBCs. Abnormalities of electrolytes (Table 1) may result from disorders of renal tubular reabsorption and secretion. These syndromes are uncommon but pathognomonic of kidney disease (). Grading of CKD is based almost exclusively on two laboratory parameters: eGFR (GFR categories 1 to 5 (G1 – G5)) and albuminuria (albuminuria categories 1 to 3 (A1 – A3)) (Table 2). It is also used for the prognosis of progression of the disease ().
Table 2

Prognosis of CKD by eGFR categories and albuminuria: KDIGO 2012

Persistent categories of albuminuriaDescription and range
A1A2A3
Normal to mildly increasedModerately increasedSeverely increased
< 3 mg/mmol3 – 30 mg/mmol> 30 mg/mmol
eGFR categories (mLmin/1.73 m2)Description and rangeG1Normal or high≥ 90
G2Mildly decreased60 – 89
G3aMildly to moderately decreased45 – 59
G3bModerately to severely decreased30 – 44
G4Severely decreased15 – 29
G5Kidney failure< 15
Green represents low risk (if no other markers of kidney disease, no CKD). Yellow represents moderately increased risk. Orange represents high risk. Red represents very high risk.(Reproduced with permission from KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int, Suppl 2013;3:1-150.)
Depending on the category, patients are classified as low-risk patients, highlighted in green, moderate risk (yellow), high risk (orange) and very high risk patients (highlighted in red). CKD testing using eGFR and ACR should be offered to people with any of the following risk factors: diabetes hypertension acute kidney injury cardiovascular disease (ischaemic heart disease, chronic heart failure, peripheral vascular disease or cerebral vascular disease) structural renal tract disease, recurrent renal calculi or prostatic hypertrophy multisystem diseases with potential kidney involvement – for example, systemic lupus erythematosus family history of end-stage kidney disease (GFR category G5) or hereditary kidney disease opportunistic detection of haematuria ().

Background

Recently, it was shown that laboratory diagnostics of chronic kidney disease in Croatia is not standardized (). There is a large heterogeneity among Croatian medical biochemistry laboratories regarding creatinine methods and used reference intervals and types of preferred samples for urine albumin (or protein). The most important issue that occured is the fact that laboratories still use non-standardized methods for creatinine results and do not report eGFR values. Also, the majority of laboratories do not measure urine albumin, especially in primary care health setting (). These facts set the background for the process of standardization and harmonization in this area of laboratory medicine. These national guidelines, based on the relevant 2012 KDIGO Guideline (), represent the first step in accomplishing this goal. Key factors for laboratories implementing the national guidelines for the diagnosis and management of CKD are: Ensure good communication between laboratory professionals and relevant clinicians, such as nephrologists or specialists in general/family medicine, Ensure all patients are provided with the same availability of laboratory diagnostics, Ensure creatinine assays are traceable to isotope dilution mass spectrometry (IDMS) method and have minimal bias and acceptable imprecision, Select the appropriate GFR estimating formula. Recommended equation is the 2009 Chronic Kidney Disease Epidemiology Collaboration (CKD – EPI) equation, In reporting the key laboratory tests (creatinine, eGFR, urine albumin-to-creatinine ratio (ACR), urine protein-to-creatinine ratio (PCR)) use the appropriate reporting units, Provide adequate information on limitations to creatinine measurement ().

Recommedations

The national recommendations are mainly based on the KDIGO 2012 guidelines, however, novel literature findings are also incorporated. Our main goal was to provide recommendations that can be easily applied in every medical biochemistry laboratory in Croatia. The draft of the recommendations was sent to numerous national and international experts for their comments. The manuscript was also made available for public consultation. All comments were carefully considered and incorporated into the final version of the recommendations. The document consists of four main parts with corresponding subheadings: Creatinine Preanalytical phase Analytical phase Postanalytical phase Pediatric considerations eGFR Equations Preanalytical phase Postanalytical phase Pediatric considerations ACR Preanalytical phase Analytical phase Postanalytical phase Pediatric considerations PCR Preanalytical phase Analytical phase Postanalytical phase Pediatric considerations. The manuscript is organized to identify critical points in four major laboratory tests used in basic laboratory diagnostics of CKD. It is rather difficult to give unique and uniform recommendations, regarding a large heterogeneity amongst methods and populations. Our intention was to point out to some weak points in pre- and analytical phase, but every laboratory must set their own specifications for method performance and handling the specimens, according to their possibilities and conditions. An easy-to-follow step-by-step approach in implementation of the recommendations is shown in Appendix 1. To ensure the better flow of information in implementing national guidelines laboratories can use the provided template (Appendix 2) ().

Creatinine

An important limiting factor in the use of predictive equations for GFR estimation is an accurate method for determining serum creatinine concentration.

Preanalytical phase

There are numerous well known preanalytical variations that affect serum creatinine concentration which are listed in the Table 3.
Table 3

Sources of errors in GFR estimation using creatinine

Source of errorExampleActions
Non-controllable variations
Non-steady stateAKILaboratory professionals and clinicians should be aware of listed limitations.For a better flow of information please consult the Appendix 2.
Factors affecting creatinine generationRaceExtremes in muscle mass (body building, anorexia)Diet/nutrition (high protein diet, creatine supplements, creatine, vegetarians)Muscle wasting diseases (muscular dystrophy, rhabdomyolysis)Ingestion of cooked meat
Factors affecting tubular secretion of creatinineDecrease by drug-induced inhibition (cimetidine, fenofibrate)Dialysis
Factors affecting extra-renal elimination of creatinineDecrease by gut creatininase by antibioticsIncreased by large volume losses of extracellular fluid
Higher GFRHigher measurement error at low serum creatinine concentrations
Partly-controllable variations
Interferences with creatinine assaySpectral interference (e.g. bilirubin, some drugs)Chemical interference (e.g. glucose, ketones, bilirubin, some drugs)Lipemia (serum delipidation with heparin and MgCl2 may cause falsely decreased creatinine concentration)For obtaining an adequate blood sample laboratory professionals should implement the valid national recommendations for venous and capillary blood sampling (References: 11, 12)For management of lipemic samples please consult a review by Nikolac et al. (Reference: 25)Regarding analytical interferences, laboratory professionals should verify the data declared by the manufacturer and define their own acceptability criteria.
AKI - acute kidney injury. GFR - glomerular filtration rate.(Reproduced with permission from KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int, Suppl 2013;3:1-150.)
The majority of listed variations are non-controllable, however both laboratory professionals and clinicians should be aware of those limitations. The laboratory professionals are referred to previously mentioned Appendix 2 which will be of assistance in communication with patients, as well as with the ordering physicians. For a minor part of variations that can be controlled regarding sample quality, laboratory professionals are referred to the published national recommendations for venous and capillary blood sampling (, ).

Stability

Creatinine, in a non-separated serum sample, which is in contact with a blood clot, is stable for 24 hours. In a separate serum sample creatinine is stable for 7 days at room temperature (20-25 °C), or stored in a refrigerator (2-8 °C). Serum samples stored at - 20 °C are stable for 3 months with 10 freeze-thaw cycles ().

Analytical phase

To universally implement eGFR based on serum creatinine measurements, standardization of routine serum creatinine measurements is required. For the measurement of serum creatinine, laboratories should use the recommended method with calibration traceable to international standard reference material and minimal bias compared to the IDMS method (). Desirable and optimal specification for imprecision, bias and total error according to biological variation database (, ) are shown in Table 4.
Table 4

Specifications for imprecision, inaccuracy and allowable total error

Desirable specificationOptimal specification
I (%)B (%)TE (%)I (%)B (%)TE (%)
Serum creatinine3.04.08.92.83.27.7
Creatinine, concentration, first morning urine11.68.727.8NANANA
Total protein, 24 hour urine17.810.740.08.95.320.0
Albumin, concentration, first morning urine18.016.446.19.97.023.3
I – specification for imprecision. B – specification for inaccuracy. TE – specification for allowable total error. NA – not applicable.
Recommended methods for serum creatinine measurements in Croatia are: photometric compensated Jaffé method traceable to IDMS method and enzymatic method traceable to IDMS method and The National Institute of Standards and Technology Standard Reference Material (NIST SRM) 967 for creatinine in serum (). However, there is emerging evidence that enzymatic creatinine assays lead to less variability in measurements of serum creatinine and are preferably used in clinical practice in order to generate more reliable GFR estimates (-). Standardization (compensation) of photometric Jaffé method involves changing the values of calibrators in terms of traceability to the IDMS method and change of corresponding intercept (or factor B, depending on the analyzer). Considering the fact that there are many creatinine assays available that may not be IDMS traceable, and that for assays which may be IDMS traceable, the information supplied does not make this clear to the user (), for new values of calibrators, controls and intercept, laboratory professionals should contact the person in charge of applications from companies providing reagents, controls and calibrators or whose analyzer is on which creatinine is measured. The list of available creatinine assays, as well as traceability information, is given in the Appendix 3. However, laboratory professionals should be aware that this list is susceptible to changes and they should always be correctly informed by the latest Information for use (IFU) leaflet. Standardization of calibration does not correct for analytical interferences. The enzymatic assays may be less influenced by non-creatinine chromogens compared to the Jaffé assays (, ), but no procedure was unaffected. The most common analytical interferences are caused by endogenous substances: high bilirubin concentration, glucose, proteins, pyruvate, β-hydroxybutyric acid, low albumin, as well as many drugs (cephalosporins, dobutamine, lidocaine) (). High bilirubin concentrations may interfere with the Jaffé method, where the assay absorbance is near the bilirubin absorbance peak of ~456 nm. Jaffé reaction may also be affected by lipemia and/or haemolysis. Haemolysed samples that contain fetal haemoglobin (HbF) interfere with the Jaffé reaction, and it is possible to obtain negative creatinine results (). Management of lipemic samples was extensively explained in the review by Nikolac et al. (). The influence of interfering substances is greater at creatinine concentrations within reference range than at higher concentrations. Magnitude and direction of bias in creatinine concentration depends on the details of implementation of the method principle (). The influence of interfering substances is less frequent with the enzymatic procedures, however no procedure is unaffected and is method and analyzer dependent (, ). Interference (endogenous or exogenous) if unrecognized lead to false laboratory result and consequently to incorrect diagnosis. To systematize corrective actions, as a part of the total quality system, when interference appears first step must be manufacturer´s method specification in which are listed interference studies conducted by the manufacturer (). However, it was shown that there are serious discrepancies between manufacturer’s declarations and measured data (). Each laboratory should verify the data declared by the manufacturer and define its own acceptability criteria (). Because urine contains relatively little or no protein, both enzymatic and Jaffé method are suitable for urine creatinine measurement ().

Postanalytical phase

When reporting serum and urine creatinine concentrations obtained by a standardized assay, laboratories should use revised reference intervals published by Croatian chamber of medical biochemists (CCMB) in 2010 (, ) which are shown in Table 5.
Table 5

Revised recommended methods and reference intervals for serum and urine creatinine measurement

AnalyteSI UnitsReference intervals
GenderAgeInterval
Serum creatinineμmol/LPrenatal (umbilical cord)46 – 86
newborn babies0 – 14 days27 – 81
male, female2 months ≤ 1 year14 – 34
male, female1 y ≤ 3 y15 – 31
male, female3 y ≤ 5 y23 – 37
male, female5 y ≤ 7 y25 – 42
male, female7 y ≤ 9 y30 – 48
male, female9 y ≤ 11 y28 – 57
male, female11 y ≤ 13 y37 – 63
male, female13 y ≤ 15 y40 – 72
maleadults (18 – 74 y)64 – 104
femaleadults (18 – 74 y)49 – 90
Urine creatinine(24 hour urine sample)mmol/24 hourmale, female3 – 8 y1.0 – 6.0
male, female9 – 12 y1.5 – 12.5
male, female13 – 17 y2.6. – 16.5
maleadults7.7 – 21.3
femaleadults5.9 – 14.1
Urine creatinine(first morning sample)mmol/Lmaleadults3.5 – 22.9
femaleadults2.5 – 19.2
y – years. (Reproduced and adapted with the permission of Croatian Chamber of Medical biochemists, document in Croatian. Available at: http://www.hkmb.hr/obavijesti/arhiva2010/arhiva_2010.html.)
The applicability of the recommended “common” reference intervals in all Croatian laboratories measuring serum creatinine concentrations were confirmed in the study conducted by Flegar-Meštrić et al. (). This fulfils the prerequisite for implementation of international guidelines for early diagnosis and prediction of progression of chronic kidney disease using glomerular filtration rate CKD-EPI estimating equation (, ).

Pediatric considerations

Children show lower reference ranges for total protein, thus the protein error in Jaffé method is considerably smaller, which, in consequence, with restandardized Jaffé-type assays, could lead to negative values in children with a decreased muscle mass (). Therefore, the only recommended method for the measurement of serum creatinine in pediatric patients (individuals younger than 18 years) is enzymatic assay (). The persisting problem of pediatric reference intervals has been substantially reduced with the establishment of a new comprehensive database of pediatric reference intervals as a part of the Canadian Laboratory Initiative in Pediatric Reference Intervals (CALIPER) study (, ). It should assist laboratorians and pediatricians in interpreting test results more accurately. There are already some transference studies with other analytical platforms and local populations, as recommended by the CLSI (, ). Laboratory professionals should also be aware of the International Federation for Clinical Chemistry and Laboratory Medicine (IFCC) Pediatric Reference Range Initiatives with many useful information on this delicate topic (). Methods for serum creatinine measurement should be traceable to IDMS method and NIST SRM 967. For urine creatinine measurement both enzymatic and Jaffé method are suitable. When reporting serum and urine creatinine values obtained by a standardized assay, laboratories should use revised reference intervals published by CCMB. The recommended method for serum creatinine measurement in pediatric patients (< 18 years) is the enzymatic assay. For pediatric reference intervals consult CALIPER database (http://www.sickkids.ca/Caliperproject/intervals/index.html) and other available literature data, such as IFCC Pediatric Reference Range Initiatives (http://www.ifcc.org/task-force-paediatric-laboratory-medicine-web-pages/paediatric-reference-range-initiatives/).

eGFR

Equations

The recommended equation for GFR estimation in adult population (≥ 18 years) is CKD-EPI equation (, , ). The equation includes four variables: serum creatinine concentration, age, sex and race (Table 6) (). Although all equations for GFR estimation are essentially mathematical abstractions that relate patients to the populations from which the equations were derived (), there is growing body of evidence that CKD-EPI equation is superior in general population (, ), as well as in diabetic patients (-).
Table 6

Recommended equations for GFR estimation

2009 CKD-EPI EQUATION (adults ≥ 18 years)
GenderSerum creatinine (µmol/L)Equation (for patients ≥ 18 years)
Female≤62eGFR =144 x (creat / 62)-0.329x (0.993)age
Female>62eGFR =144 x (creat / 62)-1.209x (0.993) age
Male≤80eGFR =141 x (creat / 80)-0.411x (0.993) age
Male>80eGFR =141 x (creat / 80)-1.209x (0.993) age
For black race use a multiplier of 1.159
SCHWARTZ EQUATION (children <18 years)
GFR (mL/min/1.73 m2) = (36.2 × height) / creatinine(height in cm, serum creatinine in µmol/L)
In situations where GFR estimating equations are limited including extremes of body size and age, conditions after limb amputation, pregnancy, severe malnutrition or obesity, muscle wasting diseases, paraplegia and quadriplegia, vegetarian diet, rapidly changing kidney function, when determining eligibility for kidney donation or adjusting dosage of toxic drugs that are excreted by the kidneys and in research projects in which estimating glomerular filtration rate is a primary goal, GFR should be measured using standardized creatinine clearance measurement (, ). eGFR may be falsely decreased after a meal of high meat content, as blood creatinine concentration increases after meal intake (). Blood creatinine is predominantly derived from muscle, e.g. a muscular young man may have increased serum creatinine concentration and a falsely lowered eGFR. eGFR increases by 2.3 mL/min/kg of lean mass in healthy men (). Low eGFR finding should be confirmed with a repeated sample taken after avoidance of meat for at least 12 hours. Spurious causes of low eGFR, such as high muscle mass, should be considered. Additionally, a low eGFR should prompt a check for proteinuria assessment (). Diagnosis, prognosis prediction and progression of CKD using eGFR is not based on comparing the values to population based reference intervals but on diagnostic values defined as categories in classification system shown in Table 2. Implementation of equations listed in Table 6, in laboratory information system is necessary for calculating eGFR using CKD-EPI equation. Recommended equations relate to white race. For calculating eGFR in black race, obtained result must be multiplied by 1.159. When reporting eGFR results, they should be rounded to a nearest whole number using the recommended units mL/min/1.73 m2. eGFR values should be reported with requests for serum creatinine concentration in adults (). Glomerular filtration rate physiologically decreases with ageing by approximately 1 mL/min/year of age (, ). Although an eGFR values < 60 mL/min/1.73 m2 are very common in older people (), it is predictive for increased risk of adverse clinical outcomes and age related diagnostic values for eGFR are not recommended in adults. Based on the biological and analytical variation of serum creatinine, the reference change value (RCV) for eGFR is about 14%. For estimation of GFR in pediatric population we recommend Schwartz equation with obligatory use of enzymatic assay for the measurement of serum creatinine concentration (, ). The equation is applicable for children from 1 to 18 years old. Routine calculation of eGFR is not recommended in children and youth (). Every eGFR result calculated by Schwartz equation above than 75 mL/min/1.73 m2 should not be reported as a whole number but as „> 75 mL/min/1.73 m2“. In children younger than 2 years of age with CKD, the GFR categories as per the adult in Table 2 do not apply; these children should be categorized as having normal, moderately reduced, or severely reduced age-adjusted GFR. No currently agreed upon set of international normative values or categories exist for GFR in children under the age of 1-2 years. However, the international pediatric nephrology community has embraced the adult CKD staging system as per the 2002 KDOQI guidelines in children over the age of 2 years (). Laboratories should implement the 2009 CKD-EPI equation for estimation of GFR. eGFR results should be reported with serum creatinine results in adults. eGFR results should be rounded to a nearest whole number using the recommended units mL/min/1.73 m2. Age related diagnostic values for eGFR are not recommended in adults. Low eGFR values should be confirmed with a repeat sample taken after avoidance of meat at least 12 hours. Additionally, spurious causes of low eGFR should be considered and should prompt a check for proteinuria. RCV for eGFR is ~14%. The recommended equation for children under 18 years is the Schwartz equation. Routine calculation of eGFR is not recommended in children and youth. Every eGFR result calculated by Schwartz equation above than 75 mL/min/1.73 m2 should be reported as „> 75 mL/min/1.73 m2”. The GFR categories (listed in the Table 2) do not apply in children under 2 years of age.

ACR

Albumin intra- and inter-individual biological variation are important factors for selecting appropriate urine sample, for the interpretation of the confirmation results and for assessing clinically significant difference in albumin concentration. ACR in the first morning urine has a significantly lower intra-individual variation, compared to the albumin concentration in 24-hour urine. This represents an important fact considering the pitfalls in collecting 24-hour urine samples (). Table 7 presents the factors affecting urinary ACR (, ).
Table 7

Factors affecting urinary ACR and PCR

FactorExamples of effectActions
Non-controllable variations
Intraindividual variabilityGenetic variabilityLaboratory professionals and clinicians should be aware of listed limitations.For a better flow of information please consult the Appendix 2.
Non-renal causes of variability in creatinine excretionAge (lower in children and elderly)Race (lower in Caucasians than black people)Muscle mass (lower in people with amputations, paraplegia, muscular dystrophy)Gender (lower in women)
Changes in creatinine excretionAKI
Partly-controllable variations
Transient elevation in albuminuriaMenstrual blood contaminationSymptomatic urinary tract infectionsExerciseOrthostatic proteinuriaOther conditions increasing vascular permeability (e.g. septicemia, significant hypertension, fever)For obtaining an adequate sample laboratory professionals should implement standards of good laboratory practice issued by CCMB, available at: http://www.hkmb.hr/povjerenstva/strucna-pitanja.htmlPatients should be thoroughly explained about possible in vivo influence factors.
Transient elevation in proteinuriaVaginal and urethral secretions contaminationExerciseDehydrationVery high protein intakeEmotional stressDiluted urine specimens can give false negative protein results
Controllable variations
Preanalytical storage conditionsDegradation of albumin before analysisAlbumin is stable in urine samples without preservatives at least one week when stored at 2-8 °C.For an extended period it is recommended to freeze the sample at - 80 °C, without centrifugation or filtration.After thawing of the sample, possible precipitates can be easily removed by dissolving the sample at 37 °C. Blurry urine samples should be centrifuged.
Degradation of total protein before analysisThe proteins are susceptible to bacterial degradation at room temperature. Analysis should be performed as quickly as possible. Samples may be stored for up to 1 week at + 4 °C, for longer storage frozen at -20 °C or at - 80 °C. Samples should be dissolved at 37 °C to prevent degradation of proteins and after homogenizing, samples should be centrifuged prior to analysis
ACR - albumin-to-creatinine ratio. PCR - protein-to-creatinine ratio. AKI - acute kidney injury. CCMB - Croatian Chamber of Medical Biochemists.(Reproduced and adapted with permission from KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int, Suppl 2013;3:1-150.)
The majority of the variations listed are non-controllable, however both laboratory professionals and clinicians should be aware of those limitations. Controllable variations include obtaining an adequate urine sample. The patient should be adequately prepared and told why a urine specimen requires to be examined. Instructions on how it should be collected should be given, ideally both orally and in written form, following the national recommendations issued by CCMB about standards of good laboratory practice in obtaining adequate urine samples (). Biological (in vivo) factors, changing the true concentration of a measured component, cause problems in the interpretation of laboratory results, although the measurement process itself is correct. They are called influence factors and patients should be adequately explained about possible interferences (). Albumin is stable in urine samples without preservatives at least one week when stored at 2-8 °C. For an extended period it is recommended to freeze the sample at –80 °C, without centrifugation or filtration. After sample thawing, possible precipitates can be easily removed by dissolving the sample at 37 °C. Blurry urine samples should be centrifuged (). Recommended methods for the measurement of urine albumin are immunochemistry assays, specific and precise at low albumin concentrations, that produce quantitative results in clinically relevant range. Albumin is mainly measured using turbidimetric assays. Currently there is no reference measurement procedure or standardized reference material recommended by the Joint Committee on Traceability in Laboratory Medicine (JCTLM). At the moment the LC-IDMS method developed at the Mayo Clinic Renal Reference Laboratory is under validation at the National Institute for Standards and technology (NIST) before being submitted to the JCTLM for listing (). Most methods are standardized against the Standard Reference Material 470 (SRM 470) distributed by the Institute for Reference Materials and Measurements (IRMM) of the European Commission (), however the NIST SRM 2925 containing pure albumin intended for calibration of LC-IDMS is now available. The commutability assessment of the NIST SRM 3666 containing albumin in frozen human urine intended for calibration of routine measurements procedures is at the moment under investigation (). Since the results are expressed in proportion to the concentration of creatinine, urine creatinine should be measured in the same urine sample. Desirable and optimal specifications for imprecision, bias and total error according to biological variation database () are shown in Table 4. Samples with very high albumin concentration may give falsely low or normal results due to the prozone effect. In this case it is necessary to repeat the analysis after dilution of the sample. The main causes of variation in urine albumin measurement are outside the analytical process, in preanalytical (as described in the previous subheading) and postanalytical phases (different units, different cut-off values, different ways of reporting the results). Other causes of variation are different forms of albumin in urine, which are significantly different from each other even between healthy individuals. Urine albumin is exposed to modifying factors such as wide range of pH and ionic strength, high concentrations of urea, glucose and ascorbate, and cleavage by peptidases (). The presence of albumin in urine should be expressed as categories of classification system shown in Table 2. The term microalbuminuria is no longer recommended. The results should be reported as ACR expressed as mg/mmol. If the presence of albumin in urine is measured as AER results should be reported using the units mg/24 hours with reference interval < 30 mg/24hours, independently of sex and age. There is no set standard encompassing all children with respect to the normal range of urinary protein (or albumin) excretion. Values vary across age, sex, puberty, the presence of obesity (high BMI) and may be modified by exercise, fever and posture (). In children with CKD any expression of abnormal urinary protein excretion may utilize proteinuria in place of albuminuria. Children older than 24 months of age are expected to achieve normal (adult) protein values (). Measure albumin preferably in a morning urine specimen. Measure urine creatinine in the same urine sample. Express the results as albumin-to-creatinine ratio (ACR) in recommended units (mg/mmol). A positive finding of albuminuria in a random sample of urine needs to be confirmed in the next morning void urine. If a more accurate estimate of albuminuria is required, it is recommended to measure albumin excretion rate (AER), with reference interval < 30 mg/24hours, independently of sex and age. In children with CKD proteinuria should be preferred over albuminuria, especially in children < 2 years of age. Adult values for AER and ACR apply for children older than 24 months of age.

PCR

Filtered serum proteins, proteins derived from the kidney and urinary tract make normal urine protein content (). Their appearance is influenced by renal, pre- and postrenal conditions (). Urine as a body fluid for clinical analysis is relatively stable, probably due to the fact that it is “stored” for hours in the bladder; hence, proteolytic degradation by endogenous proteases may be essentially complete by the time of voiding (). Total protein in urine may be increased after heavy exercise, dehydration, very high protein intake and emotional stress (). Vaginal and urethral secretions can produce false positive, and diluted urine specimens can give false negative protein results (). Because urine albumin is predominant protein in most proteinuric kidney diseases, all factors affecting urinary ACR also affect PCR (Table 7). Proteins are susceptible to bacterial degradation at room temperature. Analysis should be performed as quickly as possible. Samples may be stored for up to 1 week at + 4 °C, for longer storage frozen at –20 °C or at –80 °C. Samples should be dissolved at 37 °C to prevent degradation of proteins and after homogenizing, samples should be centrifuged prior to analysis (). There is no recommended method for measuring of total protein in the urine. The majority of laboratories use turbidimetric or colorimetric assays. These methods do not have the same analytical specificity and sensitivity for all proteins. Most methods reacts more strongly with albumin than with globulins and other non-albumin proteins. There is no reference method and no standardized reference material for urine protein recommended by JCTLM. Different methods and calibrators lead to significant between-laboratory variation. It is difficult to define a standardized reference material since a variable mixture of different proteins is measured (). Desirable and optimal specifications for imprecision, bias and total error according to biological variation database () are shown in Table 4. Results of total urine protein measurement should be reported as PCR using the units mg/mmol (Table 8).
Table 8

Protein-to-creatinine ratio’s categories in adults

CategoryPCR
P1Normal to mild proteinuria< 15.0 mg/mmol
P2Moderate proteinuria15.0 - 50.0 mg/mmol
P3Severe proteinuria> 50.0 mg/mmol
Measurement of PCR to total protein concentration, in initial assessment of proteinuria, is to overcome variation in urine concentration and dilution (). Neonates and young infants/children are both expected and allowed to have higher urinary losses of both glomerular and tubular proteinuria due to lack of maturation in the proximal tubular reabsorption of proteins. In children the quantification of total protein, as compared to the albumin only fraction, may be preferred method (). The normal ranges for albuminuria and proteinuria in children are shown in Table 9.
Table 9

Pediatric normal ranges for albuminuria and total proteinuria

Unit<6 months6 – 24 months> 24 months
PERmg/m2/day< 240< 150< 150
PCRmg/mmol/< 50< 20
AERmg/daynot knownnot known< 30
ACRmg/mmolnot knownnot known< 3
PER – Protein Excretion Rate. PCR – Protein-to-Creatinine Ratio. AER – Albumin Excretion Rate. ACR – Albumin-to-Creatinine Ratio.
Measure total protein preferably in a morning urine specimen. Measure urine creatinine in the same urine sample. Express the results as protein-to-creatinine ratio (PCR) in recommended units (mg/mmol). A positive finding of proteinuria in a random sample of urine should be confirmed in the next morning void urine. In adults, for a measure of protein excretion rate (PER) apply reference interval < 150 mg/24hours, independently of sex and age. In children, the quantification of total protein, as compared to the albumin only fraction, may be preferred method.

Conclusion

There are many issues that need to be resolved in the laboratory diagnostics of CKD in Croatia (). Although there were many potential biomarkers suggested for the early diagnosis of CKD (, ), considering the issues that were raised via the conducted survey (), we need to approach the Croatian medical biochemistry laboratories at the very basic level. The principal clinical purpose of assessing a patient’s renal function is to anticipate complications, enabling better screening and treatment decisions. Determining with great accuracy a certain physiologic parameter – actual GFR – is a less important goal () and inexpensive, easy and accurate measurement of serum creatinine could lead to reduction in the global burden of CKD (). In connection to this, the very first goal is to introduce standardized assays for creatinine measurement and eGFR reporting in all medical biochemistry laboratories. The second goal is to harmonize the choice of the sample for ACR/PCR measurement and the reporting units, consequently. The future perspectives include education in implementing the recommendations and conducting tho follow-up survey to observe the completeness and identifying „weak spots“ of the recommendations implementation process. The obtained data will be a starting point for the second edition of the recommendations. In conclusion, reporting the results of laboratory tests for the diagnosis of CKD should be aligned with the adopted general recommendations with the applicable reference intervals, diagnostic value, and the source is acknowledged criteria. An example of the recommended reporting in laboratory diagnostics of CKD is shown in Table 10.
Table 10

Recommended reporting of laboratory results

Test/AnalyteResultsUnitDiagnostic valueReference
Estimation of glomerular filtration rate (eGFR)mL/min/1,73 m2GFR categories:G1: ≥ 90G2: 60-89G3a: 45-59G3b: 30-44G4: 15-29G5: < 15KDIGO guidelines (2012.)
(U) Albumin-to-creatininemg/mmolAlbuminuria categories:A1: < 3.0A2: 3.0-30.0A3: > 30.0KDIGO guidelines (2012.)
(U) Protein-to-creatininemg/mmolProteinuria categoriesP1: < 15.0P2: 15.0-50.0P3: > 50.0KDIGO guidelines (2012.)

Informations for physicians

INFORMATIONS FOR PHYSICIANS:Standardized creatinine and evaluation of estimated glomerular filtration rate
QuestionAnswer
What is a standardized creatinine?Standardized creatinine is a result of the determination of serum creatinine by method (enzymatic or compensated Jaffé) calibrated with standard NIST SRM 967th
Why we introduce a standardized creatinine?Generally:By standardization of creatinine we compensated systematic analytical error in current non-specific methods, which allowed standardization and enabled global comparability of results of serum creatinine and application of uniform reference intervals.Specifically:Standardized creatinine is a prerequisite for the implementation of international guidelines for the early diagnosis and monitoring progression of chronic kidney disease in risk populations (hypertension, diabetes, etc.).
What is the relation of standardized creatinine results and creatinine?Used methods showed a positive bias due to analytical interferention of exogenous and endogenous substances (pseudochromogene, most of the protein molecule, glucose, ketoacids), which provides a significant contribution to the intra- and inter-laboratory variability of results. To compensate part of non-specific interfering substances, the results of standardized creatinine are generally lower than that of creatinine.Important!There is no conversion formula or factor linking standardized creatinine and creatinine.
What are the reference intervals for standardized serum creatinine for adults and how they are different from the reference intervals for creatinine?Gender (age, years)Standardized creatinineCreatinineUnits
Male (18 – 74)64 – 10479 – 125µmol/L
Female (18 – 74)49 – 9063 – 107µmol/L
What does this change in the longitudinal monitoring of renal function of the patient?Absolute results of standardized creatinine and creatinine are not comparable; relative comparability is achieved by applying appropriate reference intervals!
What is eGFR?eGFR is estimated glomerular filtration rate; calculated from serum creatinine and demographic characteristics of the patient (age, gender, race).For eGFR is not necessary to collect 24-hour urine!
Why we introduce eGFR?eGFR is a prerequisite for the implementation of international guidelines for the early diagnosis and monitoring progression of chronic kidney disease in risk populations (hypertension, diabetes, etc.)
What is the recommended equation for calculating eGFR?CKD-EPI equation with four variables (age, sex, race, concentration standardized serum creatinine) for adulthood.Schwartz equation with two variables (height of the child, the concentration of a standardized serum creatinine) for children.
What are the units for eGFR?mL/min/1.73 m2
What are the reference intervals for eGFR?There are none! We use eGFR for classification of renal impairment:
Stage of chronic kidney diseaseGlomerular filtration (mL/min/1.73 m2)
1>= 90
260 – 89
3a45 – 59
3b30 – 44
415 – 29
5<15
What are limitations of equations for estimating GFR?Schwartz equation requires the measurement of serum creatinine by enzymatic method.
When and whom can estimate GFR?All persons in whom there is no acute condition, and determined the expression level of a standardized serum creatinine.
When and to whom can not be estimate GFR?In states that follow acute changes of renal function, conditions after limb amputation and all states followed extreme changes in muscle mass.Very obese and malnourished people, pregnant women.
What is the role of creatinine clearance in the assessment of renal function?Creatinine clearance is used for the measurement of the glomerular filtration rate.However, there are numerous sources of variability that compromise the accuracy of the results (physiological - tubular secretion of creatinine, pharmacologically - diuretics, analytical - interfering, practical - errors in collecting 24-hour urine).Therefore, to estimate glomerular filtration rate is recommended eGFR calculation from serum creatinine
(Adapted from an internal document of the Merkur University Hospital, reproduced with the written permission from the authors: Vučić Lovrenčić M, Flegar-Meštrić Z, Sabljar-Matovinović M.)

Currently available creatinine reagents with the information on assay traceability – unpublished data from Radišić Biljak V and Jones G.

CompanyTest Kit NameAssay TypeSupplied Calibration Information“IDMS traceable”
Abbott-JaffeCalibrator values traceable to SRM 967 using IDMSYes
Abbott-EnzymaticCalibrator values traceable to SRM 967 using IDMSYes
AbbottCreatinineJaffeFor information on calibrator standardization, refer to Multiconstituent Calibrator package insert.Not declared
AbbottCreatinine (Enzymatic)EnzymaticFor information on calibrator standardization, refer to the MULTIGENT Clin Chem Cal package insertNot declared
Abbotti-STAT creatinineEnzymatic (whole blood)Creatinine values assigned to i-STAT controls and calibration verification materials are traceable to the US National Institute of Standards and Technology (NIST) standard reference material (SRM967). Further information available from Abbott.Yes
AccurexAutoZyme CreatinineJaffeNot specifiedNot specified
AMS DiagnosticsCreatinine ReagentJaffeUse an aqueous creatinine standard or an appropriate serum calibratorNot specified
ArkraySpotchem creatinineReagent stripSpot chem calibrator or calibration by reagent cardNot specified
Audit DiagnosticsCreatinine JaffeJaffeStandard (177 μmol/L)Not specified
Beckman CoulterCR-SJaffeIDMS (in calibrator IFU, Aqua Cal)Yes
Beckman CoulterCR-EEnzymaticIDMS (in calibrator IFU, Aqua Cal)Yes
Beckman Coulter (Olympus)CreatinineJaffeCal values Traceable NIST or Thermo Fisher Scientific 2 / NERL or reference methods.Yes
Beckman CoulterCreatinineJaffeCal values traceable to NIST SRM 967 for method A. Cal values traceable to NIST SRM 909b for method B.Yes
Beckman CoulterCreatinine (Enzymatic)EnzymaticCal values traceable to NIST SRM 967Yes
BioMed DiagnosticsCreatinineJaffe, Colorimetric, endpointCreatinine standard supplied (2.0 mg/dL)Not specified
BioMed DiagnosticsCreatinineJaffe, fixed rateCreatinine standard supplied (2.0 mg/dL)Not specified
BiotecnicaCreatinineJaffeThe concentration of the supplied standard was determined using the NIST 914a international standard.Yes
BQ KitsCreatinine Liquid Reagents AssayEnzymaticCalibrator included. Traceable to NIST SRM 914a.Yes
ChemhouseCreatinine (kinetic, Jaffes method)JaffeCreatinine standard 2 mg/dLNot specified
DiasysCreatinine FSJaffeStandard (2 mg/dL). Subtract 27 μmol/L for compensated methodYes
DiasysCreatinine PAP FSEnzymaticStandard (2 mg/dL).Yes
DiazymeEnzymatic creatinineEnzymaticcalibrator provided is traceable to NIST’s SRM 967 (GC-IDMS and LC-IDMS)Yes
Fortress diagnosticsCreatinineJaffeFor automated systems recommend a serum based calibrator to eliminate any matrix bias which may be observed with the aqueous standard. Fortress calibrator Cat BXCO321K/L/MNot specified
Fortress diagnosticsCreatinineJaffe - deproteinisedSupplied standard 177 μmol/L.Not specified
Fortress diagnosticsCreatinineJaffe - deproteinisedFor automated use we recommend a serum based calibrator to eliminate any matrix bias which may be observed with the aqueous standard. Fortress Calibrator cat. No BXC0321K/L/MYes
FujifilmDri-chem slide CRE-PIIIEnzymatic (for Fuji analyser)Traceability of Calibrators: NIST (SRM 914) Note reference material is applied to the reference method of Fujifilm corporation and is not directly applicable to the Fuji dri-chem slideYes
GenzymeCreatinine-S AssayJaffeCalibration material not suppliedNot specified
I.S.E. S.r.l.CreatinineJaffeMulticalibrator I.S.E code R030000006Not specified
IBL AmericaCreatinine Liquid Reagents AssayEnzymaticCalibrator included. Traceable to NIST SRM 914a.Yes
ID LabsIDTox Creatinine EnzymaticJaffe, microplateStandard “20 g/dL”Not specified
Ortho Clinical Diagnostics-EnzymaticNot specifiedYes
Nova BiomedicalCreatinine whole blood-Not specifiedAdjustable
PiccoloKidney CheckEnzymaticNot specifiedNot specified
Pointe ScientificCreatinine reagent setJaffeUse an NIST traceable creatinine standard (2.5 mg/dL) or serum calibrator.Not specified
Pointe ScientificCreatinine reagent setEnzymaticUse an NIST traceable creatinine standard (2.5 mg/dL) or serum calibrator.Not specified
RobonikPrietest CreatinineJaffeStandard provided (2 mg/dL)Not specified
RocheCreatinine Jaffe methodJaffeThis method has been standardised against IDMS (Isotope Dilution Mass Spectrometry). For the USA the method has been standardised against a primary reference mterial (SRM 914).Yes
RocheCreatinine Jaffe Gen.2JaffeThis method has been standardised against IDMS (Isotope Dilution Mass Spectrometry). For the USA the method has been standardised against a primary reference material (SRM 914 and SRM 967 (IDMS)).Yes
RocheCrea plusEnzymaticThis method has been standardised against IDMS (Isotope Dilution Mass Spectrometry).Yes
RocheCrea plus ver.2EnzymaticThis method has been standardised against IDMS (Isotope Dilution Mass Spectrometry).Yes
SekisuiEnzymatic Creatinine 265 seriesEnzymaticNot specifiedYes
SekisuiEnzymatic Creatinine 265 seriesJaffeNot specifiedYes
SentinelCreatinineJaffeIFU not seenNot specified
SentinelMultigent CreatinineEnzymaticcorrelation with Roche enzymatic (on DXc)Yes
Siemens -Advia-JaffeIFU not seen - Claim at NKDEPYes
Siemens - Advia-EnzymaticIFU not seen - Claim at NKDEPYes
Siemens - Dimension-JaffeNot specifiedNo
Spectrum (Egyptian Company for Biotechnology)Creatinine - Jaffe (single reagent)JaffeStandard 2 mg/dLNot specified
SpinreactCreatinineJaffeCalibration with aqueous calibrator may cause a systematic error in automated procedures. In these cases it is recommended to use a serum calibrator.Not specified
SpinreactCreatinineEnzymaticCalibration with aqueous calibrator may cause matrix related bias, it is recommended to use a serum based calibrator.Not specified
StanbioCreatinine Liquicolor test (kinetic)JaffeStandard includedNot specified
ThermoInfinity Creatinine Liquid stable reagentJaffe“Calibrator or suitable aqueous creatinine standard”. “An aqueous standard or serum based calibrator with and assigned value traceable to a primary standard (e.g. NIST or IRMM) is recommended”Not specified
ThermoCreatinine reagent - EnzymaticEnzymaticAn aqueous standard or serum based calibrator with an assigned value traceable to a primary standard (e.g. NIST or IRMM) is recommendedNot specified
VITROSCIENTCreatinine (fixed rate)JaffeStandard not definedNot specified
VITROSCIENTCreatinine (fixed rate)Jaffe, deproteinisedStandard not definedNot specified
WAKOCreatinine M L-typeEnzymaticWako system calibrator (available separately)Not specified
WienerCreatinina directaJaffeStandard 20 mg/L creatinine solutionNot specified
WienerCreatinina directaEnzymaticWiener Lab Calibrator (3 values for creatinine depending on Wiener method)Not specified
DiaSystem Scandinavia ABCreatinine JaffeJaffeCalibrators traceable to NIST 9167, subtract 27 μmol/LYes
MedichemEnzymaticNot specifiedNot specified
RandoxEnzymaticNot specifiedNot specified
DiachemCREATININE ENZYMATICEnzymaticCalibration: S2: Creatinine standard found in the kit or Roche C.F.A.S. (Calibrator for automated system) or Roche cfas or Randox cal Li or level IINot specified
Pariksha BiotekCREATININE - 2R KITJaffeNot specifiedNot specified
Coral Clinical SystemsCreatinine Kit (Mod Jaffe’s kinetic method)JaffeSupplied standard 177 μmol/L. “standard is traceable to standard reference material (SRM) 909b.”Not specified
Ensure BiotechCreatinine EPKJaffeSupplied standard 177 μmol/L.Not specified
Kamineni Life SciencesLifechem Creatinine-LRJaffeSupplied standard 177 μmol/L.Not specified
KEE GAD BiogenCreatinine (Jaffe’s method)JaffeSupplied standard 177 μmol/L.Not specified
RecombigenCreatinine (Alkaline Picrate method)Jaffe with deproteinisationSupplied standard 177 μmol/L.Not specified
AGGAPE DiagnosticsEnzymatic CreatinineEnzymaticSupplied standard 177 μmol/L.Not specified
Linear Chemicals SLCromatest CreatinineJaffeSupplied standard 177 umol/L. “Organic matrix based primary standard. Concentration value is traceable to Standard Reference Material 914a.”
Polymer TechnologyPTS PANELS Creatinine Test StripsEnzymatic test strips for use in CadioChek PA analyserpredicate device comparison: A = 0.93 x B +0.49 mg/dLNot specified
bioMerieux SACréatinine cinétique (CREA)Jaffe- Use Calimat (Ref. 62 321): multiparametric calibrator linked with SRM 909or - Use Reagent 1 (Ref. 61 162) linked with SRM 914Titer of Reagent 1:132.6 μmol/LAqueous solution prepared using 99% pure creatinineNot specified
Dijagnostika d.o.o.Kreatinin kinetičkiJaffeAn aqueous standard or serum based calibrator with and assigned value traceable to a primary standard (eg NIST or IRMM) is recommendedNot specified
Dijagnostika d.o.o.Kreatinin DST(liquid)JaffeAn aqueous standard or serum based calibrator with and assigned value traceable to a primary standard (eg NIST or IRMM) is recommendedNot specified
Horiba ABX SASABX Pentra Creatinine 120 CPJaffeABX Pentra Multical requiredNot specified
Horiba ABX SASABX Pentra Enzymatic Creatinine CPEnzymaticABX Pentra Multical requiredNot specified
Humanauto-CREATININE liquicolorJaffeauto-CREATININE is calibrated with AUTOCAL, which is traceable to the reference material SRM 909b level 2.Not specified
HumanCREATININE (ENZYM) liquicolorEnzymaticThe method is traceable to the SRM 909c.Not specified
HumanCREATININE liquicolorJaffeThe method is traceable to the SRM 909bNot specified
  48 in total

1.  The standardization of the urine albumin assays: no longer deferrable.

Authors:  Maria Stella Graziani; Mario Plebani
Journal:  Clin Chem Lab Med       Date:  2015-10       Impact factor: 3.694

2.  Using glomerular filtration rate estimating equations: clinical and laboratory considerations.

Authors:  Andrew S Levey; John H Eckfeldt
Journal:  Clin Chem       Date:  2015-08-21       Impact factor: 8.327

Review 3.  Estimating equations for glomerular filtration rate in the era of creatinine standardization: a systematic review.

Authors:  Amy Earley; Dana Miskulin; Edmund J Lamb; Andrew S Levey; Katrin Uhlig
Journal:  Ann Intern Med       Date:  2012-02-06       Impact factor: 25.391

Review 4.  How to estimate GFR in children.

Authors:  Joris R Delanghe
Journal:  Nephrol Dial Transplant       Date:  2008-05-29       Impact factor: 5.992

5.  Closing the gaps in pediatric laboratory reference intervals: a CALIPER database of 40 biochemical markers in a healthy and multiethnic population of children.

Authors:  David A Colantonio; Lianna Kyriakopoulou; Man Khun Chan; Caitlin H Daly; Davor Brinc; Allison A Venner; Maria D Pasic; David Armbruster; Khosrow Adeli
Journal:  Clin Chem       Date:  2012-02-27       Impact factor: 8.327

Review 6.  [Biological analysis of proteinuria in the laboratory: quantitative features].

Authors:  T Le Bricon
Journal:  Ann Biol Clin (Paris)       Date:  2001 Nov-Dec       Impact factor: 0.459

7.  Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus.

Authors:  David B Sacks; Mark Arnold; George L Bakris; David E Bruns; Andrea Rita Horvath; M Sue Kirkman; Ake Lernmark; Boyd E Metzger; David M Nathan
Journal:  Clin Chem       Date:  2011-05-26       Impact factor: 8.327

8.  Short-term storage stability of serum angiotensin-converting enzyme (ACE) activity.

Authors:  Marija Culjak; Nora Nikolac; Ana-Maria Simundic
Journal:  Clin Chim Acta       Date:  2015-05-07       Impact factor: 3.786

9.  Interference testing.

Authors:  Goce Dimeski
Journal:  Clin Biochem Rev       Date:  2008-08

10.  Applicability of common reference intervals for serum creatinine concentrations to the Croatian population.

Authors:  Zlata Flegar-Mestrić; Sonja Perkov; Barbara Simonović; Dubravka Juretić
Journal:  Clin Chem Lab Med       Date:  2010-02       Impact factor: 3.694

View more
  10 in total

1.  Multiparametric quantitative renal MRI in children and young adults: comparison between healthy individuals and patients with chronic kidney disease.

Authors:  Jonathan R Dillman; Stefanie W Benoit; Deep B Gandhi; Andrew T Trout; Jean A Tkach; Katherine VandenHeuvel; Prasad Devarajan
Journal:  Abdom Radiol (NY)       Date:  2022-03-02

2.  The first step in creating national Chronic Kidney Disease (CKD) guidelines - a questionnaire.

Authors:  Vanja Radišić Biljak; Anders Grubb; Isabel Cachapuz Guerra; Etienne Cavalier; Stella Raymondo; Rosa Sierra-Amor; Michele Mussap; Shanthi Naidu Kamathan; Dogan Yucel; Pradip Datta; Takashi Wada; Flavio F Alcantara
Journal:  Biochem Med (Zagreb)       Date:  2019-08-05       Impact factor: 2.313

3.  Development and Validation of a Prediction Model for Elevated Arterial Stiffness in Chinese Patients With Diabetes Using Machine Learning.

Authors:  Qingqing Li; Wenhui Xie; Liping Li; Lijing Wang; Qinyi You; Lu Chen; Jing Li; Yilang Ke; Jun Fang; Libin Liu; Huashan Hong
Journal:  Front Physiol       Date:  2021-08-23       Impact factor: 4.566

4.  Reference values of urine protein/creatinine ratio in healthy Dalian adults.

Authors:  Tong Liu; Bang-Lu Xue; Bin Du; Tong Cui; Xin Gao; Yue-Ying Wang; Bo Wang; Jin-Long Wei
Journal:  J Clin Lab Anal       Date:  2021-10-07       Impact factor: 2.352

5.  AN INFANT WITH IDIOPATHIC HYPERCALCIURIA AND NEPHROLITHIASIS ASSOCIATED WITH CYP24A1 ENZYME POLYMORPHISM: A CASE REPORT.

Authors:  Ivana Trutin; Iva Škorić
Journal:  Acta Clin Croat       Date:  2022-02       Impact factor: 0.780

6.  The positive correlation between brachial-ankle pulse wave velocity and aortic diameter in Chinese patients with diabetes.

Authors:  Liping Li; Wenhui Xie; Qingqing Li; Huashan Hong
Journal:  J Clin Hypertens (Greenwich)       Date:  2022-07-27       Impact factor: 2.885

7.  Development and Evaluation of a Quantitative Fluorescent Lateral Flow Immunoassay for Cystatin-C, a Renal Dysfunction Biomarker.

Authors:  Satheesh Natarajan; Maria C DeRosa; Malay Ilesh Shah; Joseph Jayaraj
Journal:  Sensors (Basel)       Date:  2021-05-03       Impact factor: 3.576

8.  Task Force on CKD - We have Come a Long Way.

Authors:  Graham R D Jones
Journal:  EJIFCC       Date:  2017-12-19

9.  A Pathway to National Guidelines for Laboratory Diagnostics of Chronic Kidney Disease - Examples from Diverse European Countries.

Authors:  Vanja Radišić Biljak; Kristin Moberg Aakre; Dogan Yucel; Anne-Sophie Bargnoux; Jean-Paul Cristol; Laurence Piéroni
Journal:  EJIFCC       Date:  2017-12-19

10.  Assessment of the degree of adherence of medical laboratories to KDIGO 2012 guideline for evaluation and management of CKD in Czechia and Slovakia.

Authors:  Šálek Tomáš; Friedecký Bedřich; Kratochvíla Josef; Pelinková Květa; Budina Marek
Journal:  Biochem Med (Zagreb)       Date:  2019-08-05       Impact factor: 2.313

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.